510 related articles for article (PubMed ID: 11525295)
1. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
3. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.
Pienta KJ
Semin Oncol; 2001 Aug; 28(4 Suppl 15):3-7. PubMed ID: 11685722
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for androgen-independent prostate cancer.
Petrylak DP
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):31-5. PubMed ID: 12198636
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Urakami S; Yoshino T; Kikuno N; Imai S; Honda S; Yoneda T; Kishi H; Shigeno K; Shiina H; Igawa M
Urology; 2005 Mar; 65(3):543-8. PubMed ID: 15780373
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in prostate cancer.
Small EJ
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
[TBL] [Abstract][Full Text] [Related]
11. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
12. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
13. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Sitka Copur M; Ledakis P; Lynch J; Hauke R; Tarantolo S; Bolton M; Norvell M; Muhvic J; Hake L; Wendt J
Semin Oncol; 2001 Aug; 28(4 Suppl 15):16-21. PubMed ID: 11685724
[TBL] [Abstract][Full Text] [Related]
16. Interaction between Herceptin and taxanes.
DiƩras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
[TBL] [Abstract][Full Text] [Related]
18. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
19. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]